ArticleNucleic acids research2012
Engineering synthetic TAL effectors with orthogonal target sites.
Article in Nucleic acids research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 155 citations in OpenAlex.
- Trial
- Human Synthetic Biology and Programmable Gene Regulation Control.Annual review of genomics and human genetics · 2025Review
- Partitioning of a 2-bit hash function across 66 communicating cells.Nature chemical biology · 2025Article
- Hierarchical metabolic engineering for rewiring cellular metabolism.FEMS microbiology reviews · 2025Review
- Systems for Targeted Silencing of Gene Expression and Their Application in Plants and Animals.International journal of molecular sciences · 2024Review
- Circular single-stranded DNA as switchable vector for gene expression in mammalian cells.Nature communications · 2023Article
- Construction of the genetic switches in response to mannitol based on artificial MtlR box.Bioresources and bioprocessing · 2023Article
- A single promoter-TALE system for tissue-specific and tuneable expression of multiple genes in rice.Plant biotechnology journal · 2022Article
- Gene-circuit therapy on the horizon: synthetic biology tools for engineered therapeutics.Acta biochimica Polonica · 2021Review
- Recent developments and applications of genetic transformation and genome editing technologies in wheat.TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik · 2020Review
- Tunable self-cleaving ribozymes for modulating gene expression in eukaryotic systems.PloS one · 2020Article
- Computational analysis of viable parameter regions in models of synthetic biological systems.Journal of biological engineering · 2019Article
- Engineered dCas9 with reduced toxicity in bacteria: implications for genetic circuit design.Nucleic acids research · 2018Article
- Designing cell function: assembly of synthetic gene circuits for cell biology applications.Nature reviews. Molecular cell biology · 2018Review
- Engineering altered protein-DNA recognition specificity.Nucleic acids research · 2018Review
- A small, portable RNA device for the control of exon skipping in mammalian cells.Nucleic acids research · 2018Article
- RNA-binding specificity landscapes of designer pentatricopeptide repeat proteins elucidate principles of PPR-RNA interactions.Nucleic acids research · 2018Article
- Genetic tool development and systemic regulation in biosynthetic technology.Biotechnology for biofuels · 2018Review
- Scaling up genetic circuit design for cellular computing: advances and prospects.Natural computing · 2018Article
- A multiplexable TALE-based binary expression system for in vivo cellular interaction studies.Nature communications · 2017Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The ability to engineer biological circuits that process and respond to complex cellular signals has the potential to impact many areas of biology and medicine. Transcriptional activator-like effectors (TALEs) have emerged as an attractive component for engineering these circuits, as TALEs can be designed de novo to target a given DNA sequence. Currently, however, the use of TALEs is limited by degeneracy in the site-specific manner by which they recognize DNA. Here, we propose an algorithm to computationally address this problem. We apply our algorithm to design 180 TALEs targeting 20 bp cognate binding sites that are at least 3 nt mismatches away from all 20 bp sequences in putative 2 kb human promoter regions. We generated eight of these synthetic TALE activators and showed that each is able to activate transcription from a targeted reporter. Importantly, we show that these proteins do not activate synthetic reporters containing mismatches similar to those present in the genome nor a set of endogenous genes predicted to be the most likely targets in vivo. Finally, we generated and characterized TALE repressors comprised of our orthogonal DNA binding domains and further combined them with shRNAs to accomplish near complete repression of target gene expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.